Biotechnology

BIOSTAR PHARM-B

BIOSTAR PHARM-B released FY2024 Q1 earnings on August 28, 2025 (BJT) with actual revenue of HKD 17.95 M and EPS of HKD -0.1092

BIOSTAR PHARM-B released FY2024 Q2 earnings on August 28, 2025 (BJT) with actual revenue of HKD 17.8 M and EPS of HKD -0.1083

BIOSTAR PHARM-B released FY2025 Q1 earnings on August 28 (BJT), actual revenue HKD 7.918 M, actual EPS HKD -0.0793

BIOSTAR PHARM-B released FY2025 Semi-Annual Earnings on August 28 Pre-Market (BJT), actual revenue HKD 16.01 M, actual EPS HKD -0.1604

BIOSTAR PHARM-B released FY2025 Q2 earnings on August 28 Pre-Market (BJT), actual revenue HKD 8.092 M, actual EPS HKD -0.0811

BIOSTAR PHARM-B to Release FY2025 Semi-Annual Earnings on August 28, 2025 (BJT)

BIOSTAR PHARM-B released FY2024 earnings on June 30 Pre-Market BJT, actual revenue HKD 77.79 M (forecast HKD 91.49 M), actual EPS HKD -0.4415 (forecast HKD -0.567)

BIOSTAR PHARM-B to Release FY2024 Earnings on March 31, Pre-Market BJT; Forecast Revenue 91.92 M HKD, EPS -0.5696 HKD

BIOSTAR PHARM-B released FY2024 Semi-Annual earnings on October 22 (BJT), actual revenue HKD 35.74 M, actual EPS HKD -0.2175

DATA UNION CAP

MEDIA CHINESE

WMCH GLOBAL

ALMANA

PAK TAK INT'L

STERLING GP

GOME RETAIL

CENTRAL DEV H

CAPITAL REALM

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap